Maze Therapeutics, Inc.
MAZENASDAQHealthcareBiotechnology
Latest quote
$29.43
+$0.50 · +1.73%
MAZE company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
2
Overpriced
Momentum
51
Neutral
Sentiment
58
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jason Coloma
- Listed since
- Jan 31, 2025
- Employees
- 141
Market position
- Volume
- 280.59K
- 0.48× average
- Average volume
- 580.58K
- Average daily volume
- Market cap
- 1.63B USD
- Beta
- 2.21
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.61B USD
- P/E (TTM)
- -10.74×
- P/B (TTM)
- 3.83×
- P/S (TTM)
- 81.44×
- EV / EBITDA
- -12.54×
- Earnings yield
- -7.36%
- Free cash flow yield
- -6.33%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 95.28%
- Operating margin
- -728.06%
- Net margin
- -667.95%
- Return on equity
- -36.94%
- Return on assets
- -33.02%
- Return on invested capital
- -37.67%
Financial health
- Debt / equity
- 0.13×
- Current ratio
- 15.5×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | 167.5M USD | — | — |
| Cost of goods sold | 2.4M USD | — | — | — |
| Gross profit | −2.4M USD | 167.5M USD | — | — |
| Research and development | 108.45M USD | 83.5M USD | 73.95M USD | 88.19M USD |
| Selling, general, and administrative | 34.45M USD | 26.42M USD | 24.61M USD | 22.83M USD |
| Operating expenses | 140.5M USD | 109.91M USD | 98.55M USD | 111.03M USD |
| Interest income | 11.78M USD | 4.65M USD | 1.97M USD | 2.03M USD |
| Depreciation and amortization | 2.4M USD | 3.3M USD | 4.09M USD | 3.82M USD |
| Operating income | −142.9M USD | 57.59M USD | −98.55M USD | −111.03M USD |
| Net income | −131.12M USD | 52.23M USD | −100.42M USD | −114.94M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
6 ratingsMAZE news
MAZE peers
ETFs holding MAZE
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI38.01M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM26.21M0.03%81.62B USD0.19%$299.96+0.77%
State Street SPDR S&P Pharmaceuticals ETFXPH9.39M1.67%560.87M USD0.35%$72.80+0.71%
Vanguard Extended Market ETFVXF8.78M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO7.99M0.05%15.16B USD0.24%$387.37+1.24%
iShares Biotechnology ETFIBB7.49M0.07%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO5.33M0.03%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA3.87M0.02%23.1B USD0.03%$34.83+0.52%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 38.01M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 26.21M
- Weight
- 0.03%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
State Street SPDR S&P Pharmaceuticals ETFXPH- Market value
- 9.39M
- Weight
- 1.67%
- AUM
- 560.87M USD
- Expense ratio
- 0.35%
- Price / 1D
- $72.80+0.71%
Vanguard Extended Market ETFVXF- Market value
- 8.78M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 7.99M
- Weight
- 0.05%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
iShares Biotechnology ETFIBB- Market value
- 7.49M
- Weight
- 0.07%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 5.33M
- Weight
- 0.03%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 3.87M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research MAZEresearch.disclaimer